Keros Therapeutics (KROS) Net Margin (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Net Margin came in at 12479.26% in Q4 2025, down 1096624.0% YoY from N/an in Q4 2024, and down 24111.13% on a QoQ basis from 51.54% in Q3 2025.
Keros Therapeutics (KROS) Net Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of Net Margin data on file, last reported at 12479.26% in Q4 2025.
- Quarterly Net Margin fell 1096624.0% year-over-year to 12479.26% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 35.7% (up 536884.0% YoY) and the FY2025 annual result came in at 35.68%, up 531323.0% from the prior year.
- Net Margin eased to 12479.26% in Q4 2025, from 51.54% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 70.27% in Q1 2025 to a low of 493000.0% in Q3 2023.
- A 5-year average of 51389.39% and a median of 6996.14% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin soared 47935155 bps — and 2025, when it slumped 1096624 bps.
- Tracing KROS's Net Margin over 5 years: stood at 38.77% in 2021, then sank by 247 bps to 134.37% in 2022, then plunged by 20844 bps to 28141.96% in 2023, then surged by 95 bps to 1513.02% in 2024, then sank by 725 bps to 12479.26% in 2025.
- The last three Net Margin figures came in at 12479.26% (Q4 2025), 51.54% (Q3 2025), and 168.96% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,479.26% |
| Sep 30, 2025 | -51.54% |
| Jun 30, 2025 | -168.96% |
| Mar 31, 2025 | 70.27% |
| Dec 31, 2024 | -1,513.02% |
| Sep 30, 2024 | -13,648.45% |
| Mar 31, 2024 | -51,944.58% |
| Dec 31, 2023 | -28,141.96% |
| Sep 30, 2023 | -493,000.00% |
| Mar 31, 2022 | -134.37% |
| Dec 31, 2021 | -38.77% |
| Jun 30, 2021 | -15,622.00% |
| Dec 31, 2019 | -128.04% |
| Sep 30, 2019 | -159.96% |
| Jun 30, 2019 | -132.12% |
| Mar 31, 2019 | -145.32% |